ELCC 2026: Tumor-Agnostic ctDNA Methylation for Recurrence Prediction

At the ELCC Congress 2026, Jonathan Lee, medical student at the University of Southern Denmark, presented a study of approximately 100 patients with curatively resected lung cancer followed for two years. Using a tumor-agnostic approach based on methylated ctDNA, blood samples collected preoperatively and at six months were analyzed. Baseline ctDNA levels were associated with recurrence, supporting its potential for risk stratification and guiding adjuvant therapy.